Depressive Symptomatology Is Associated With Smaller Reductions in Drug Cue Reactivity During Extended-Release Naltrexone Treatment of Opioid Use Disorder
- PMID: 37074295
- PMCID: PMC10119768
- DOI: 10.4088/JCP.22br14567
Depressive Symptomatology Is Associated With Smaller Reductions in Drug Cue Reactivity During Extended-Release Naltrexone Treatment of Opioid Use Disorder
Figures
References
-
- Li Q, Li W, Wang H, et al. Predicting subsequent relapse by drug-related cue-induced brain activation in heroin addiction: an event-related functional magnetic resonance imaging study. Addict Biol 2015;20(5):968–978. - PubMed
-
- Shi Z, Jagannathan K, Padley JH, et al. The role of withdrawal in mesocorticolimbic drug cue reactivity in opioid use disorder. Addict Biol 2021;26(4):e12977. - PubMed
-
- Krupitsky E, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Silverman BL. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet 2011;377(9776):1506–1513. - PubMed
-
- Krupitsky E, Nunes EV, Ling W, Gastfriend DR, Memisoglu A, Silverman BL. Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness. Addiction 2013;108(9):1628–1637. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
